WHO grants EUL for Covovax

First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine

WHO to take call on Covaxin's EUL on October 26th

The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies

Japanese pharma firms turn to CDMOs early as peptide complexity rises

Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages

Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod

The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort

Lupin receives FDA approval for biosimilar Armlupeg

Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA

Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia